A story by numbers

Meningococcal Disease

Every 8 minutes
1 person dies of meningococcal meningitis worldwide[1]

Meningococcal disease can kill within **24 hours** and is easily misdiagnosed[2,3]

Up to 1 out of 10
cases may end in death[2]

Up to 1 out of 5
survivors may suffer subsequent disability[2,3]

kidney failure[4] | **brain damage**[3] | **loss of limb**[3] | **hearing loss**[2,3]

Infants in whom protective antibodies have not yet developed are at highest risk of contracting meningococcal disease[3,5]

Adolescents and young adults can also be at risk of contracting meningococcal disease due to social factors, such as living in college dormitories[6]

The most vulnerable populations: **infants and adolescents**[5,6]

A B C W X Y

Six serogroups of Neisseria meningitidis cause the majority of cases of meningococcal disease around the world.[7,8]



Africa[8] A C W X

Australia[8] B C

Europe[8] B C Y

North America[8] B C Y

South America[8] B C Y W

Five serogroups are vaccine-preventable and are included on many countries' vaccination schedules or are currently being integrated into vaccination schedules[9,10,11]

1. Naghavi, Mohsen, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015, 385: 117-171.
2. World Health Organization (WHO). Meningococcal meningitis. Factsheet #141. November 2015 update. Available at: http://www.who.int/ mediacentre/factsheets/fs141/en/. Accessed November 2015.
3. Rosenstein NE, et al. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
4. NMA, (2015). Statistics and Disease Facts - NMA. [online] Available at: http://www.nmaus.org/disease-prevention-information/statistics -and-disease-facts/. Accessed November 2015.
5. Jafri, Rabab Z., et al. Global epidemiology of invasive meningococcal disease. Population Health Metrics, 2013; 11: 17. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848799/. Accessed November 2015.
6. Centers for Disease Control and Prevention (CDC). Prevention and Control of Meningococcal Disease; Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report (MMWR). 2013; 62(2):1-13. Available at: http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf. Accessed November 2015.
7. World Health Organization (WHO). Meningococcal vaccines position paper. Weekly Epidemiological Record No. 47, 2011, 86, 521-540. Available at: http://www.who.int/wer/2011/wer8647.pdf. Accessed November 2015.
8. Dbaibo, G., Khinkarly, R. and Hedari, C. (2014). Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. IDR, p.85.
9. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report—Vaccine-preventable diseases—invasive bacterial diseases 2014. Published 11 Feb 2015. Available at: http://www.ecdc.europa.eu/en/publications/Publications/AER-VPDIBD-2014.pdf. Accessed November 2015.
10. European Centre for Disease Prevention and Control (ECDC). Vaccine Schedule: Recommended immunisations for meningococcal disease. Available at: http://vaccineschedule.ecdc.europa.eu/Pages/Scheduler.aspx. Accessed November 2015.
11. Terranella, A., et al. Infect Drug Resist. 2011; 4: 161-169. doi:10.2147/IDR.S21545 https://www.dovepress.com/meningococcal-conjugate-vaccines-optimizing-global-impact-peer-reviewed-article-IDR Accessed February 2016.

Date of preparation: 11-02-2016

VGBU/BEX/0012/15